Prenatal testing for maternal serum alpha-fetoprotein

Area of Science:

• Maternal-fetal medicine
• Prenatal diagnostics
• Biochemical screening

Background:

• Maternal serum alpha-fetoprotein (AFP) is a key biomarker in prenatal screening.
• Accurate dating of gestation is essential for interpreting AFP levels.
• Neural tube defects and chromosomal anomalies are significant pregnancy complications.

Purpose of the Study:

• To emphasize the importance of universal maternal serum AFP screening.
• To outline the diagnostic pathways for abnormal AFP levels.
• To highlight the clinical and medicolegal necessity of offering AFP testing.

Main Methods:

• Measurement of maternal serum alpha-fetoprotein (AFP) levels.
• Gestational dating at 16 to 20 weeks.
• Follow-up diagnostic procedures including ultrasonography and amniocentesis.

Main Results:

• Elevated AFP levels indicate a need for ultrasonography and potentially amniocentesis to rule out neural tube defects.
• Low AFP levels suggest possible chromosomal anomalies, necessitating amniocentesis for confirmation.
• AFP screening is identified as a cost-effective measure.

Conclusions:

• Maternal serum AFP screening is a vital component of prenatal care.
• Abnormal AFP levels require prompt and appropriate diagnostic follow-up.
• Offering AFP screening to all pregnant women is medically and legally imperative.